机构：[1]Division of Thoracic Surgery, Sichuan Cancer Hospital & Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, China.四川省人民医院四川省肿瘤医院[2]Department of Esophageal Surgery, National Cancer Center Hospital, Tokyo, Japan[3]Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Esophageal squamous cell carcinoma (ESCC) is one of the most common malignancies worldwide, especially in East Asia. ESCC accounts for more than 90% of esophageal cancer. Currently, neoadjuvant therapy in combination with surgical resection is the mainstay of treatment. However, the overall survival rate of patients with locally advanced ESCC is not satisfactory even when treated following the standard treatment guidelines. With neoadjuvant chemoradiotherapy, chemotherapy, or emerging immunotherapy, continuous exploration of efficacy in relation to ESCC is expected to improve overall survival further. Here, we review and summarize current evidence for efficacy of preoperative therapy for locally advanced ESCC.
基金：
Program of Science and Technology of Sichuan Province [2018SZ0199]; International Cooperation Projects of Science and Technology of Sichuan Province [2020YFH0169]
第一作者机构：[1]Division of Thoracic Surgery, Sichuan Cancer Hospital & Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, China.
通讯作者：
通讯机构：[1]Division of Thoracic Surgery, Sichuan Cancer Hospital & Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, China.[3]Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China[*1]Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.[*2]Division of Thoracic Surgery, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), No. 55, Section 4,South Renmin Road, Chengdu 610041, China.
推荐引用方式(GB/T 7714)：
Leng Xue-Feng,Daiko Hiroyuki,Han Yong-Tao,et al.Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma[J].ANNALS OF THE NEW YORK ACADEMY OF SCIENCES.2020,1482(1):213-224.doi:10.1111/nyas.14508.
APA：
Leng, Xue-Feng,Daiko, Hiroyuki,Han, Yong-Tao&Mao, You-Sheng.(2020).Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma.ANNALS OF THE NEW YORK ACADEMY OF SCIENCES,1482,(1)
MLA：
Leng, Xue-Feng,et al."Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma".ANNALS OF THE NEW YORK ACADEMY OF SCIENCES 1482..1(2020):213-224
综合性期刊